Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01564277 · ClinicalTrials.gov registry record · Phase 2
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01564277 is a Phase 2 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 24 participants.
The verdict
NCT01564277, a Phase 2 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving rasburicase together with allopurinol works in treating patients with hematologic malignancies. Rasburicase may reduce the level of uric acid in the blood. Allopurinol may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known which dose of rasburicase is more effective in treating hematologic malignancies when given together with or without allopurinol.
Interventions
- DRUG allopurinol
- DRUG rasburicase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-09-29 |
| Est. Completion | 2016-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01564277
The ClinicalTrials.gov registry entry for NCT01564277 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which allopurinol is the first listed.
NCT01564277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01564277 about?
NCT01564277 is a clinical study titled "Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies". This randomized phase II trial studies how well giving rasburicase together with allopurinol works in treating patients with hematologic malignancies. Rasburicase may reduce the level of uric acid in the blood. Allopurinol may stop the growth of cancer cells by blocking some of the enzymes needed fo...
What is the current status of trial NCT01564277?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2011-09-29. Estimated completion is 2016-05-28.
What interventions are being tested in trial NCT01564277?
The interventions under investigation include: allopurinol (DRUG), rasburicase (DRUG).
Who is sponsoring clinical trial NCT01564277?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.